Back to results
US 10,864,215 B2Granted
Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
AssigneeMemorial Sloan Kettering Cancer Center
InventorsEulalia Baselga, Pau Castel, Jose T. Baselga
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase (“PI3K”).
Claims9
A method of treating a venous malformation in a subject in need thereof, comprising administering to the subject an effective amount of BYL719 (Alpelisib),
- wherein the venous malformation is not associated with congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies syndrome (CLOVES), Klippel-Trenaunay syndrome (KTS), or fibro-adipose vascular anomaly (FAVA), and
- wherein the subject has a gain-of-function mutation in the PI3K/AKT pathway.
Dependencies are inferred from the claim text.